TMP269

TMP269 is a potent and selective small molecule inhibitor of Class IIa histone deacetylases (HDACs), specifically targeting HDAC4, HDAC5, HDAC7, and HDAC9. Developed by Tempero Pharmaceuticals (a subsidiary of GSK), it is primarily utilized as a chemical probe to investigate the biological functions of Class IIa HDACs, which differ from Class I HDACs by acting as transcriptional regulators rather than active histone modifiers. In preclinical research, particularly in pancreatic cancer models, TMP269 has been shown to activate the FoxO3a transcription factor, leading to G1/S cell cycle arrest through the upregulation of p21Waf1/Cip1 and the downregulation of cyclins and cyclin-dependent kinases. It has also demonstrated synergistic anti-tumor effects when combined with proteasome inhibitors such as carfilzomib.